GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Anteris Technologies Ltd (OTCPK:AMEUF) » Definitions » 3-Year Revenue Growth Rate

Anteris Technologies (Anteris Technologies) 3-Year Revenue Growth Rate : -44.80% (As of Dec. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Anteris Technologies 3-Year Revenue Growth Rate?

Anteris Technologies's Revenue per Share for the six months ended in Dec. 2023 was $0.07.

During the past 12 months, Anteris Technologies's average Revenue per Share Growth Rate was -23.30% per year. During the past 3 years, the average Revenue per Share Growth Rate was -44.80% per year. During the past 5 years, the average Revenue per Share Growth Rate was -49.80% per year. During the past 10 years, the average Revenue per Share Growth Rate was -29.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Anteris Technologies was 11.00% per year. The lowest was -50.90% per year. And the median was -34.60% per year.


Competitive Comparison of Anteris Technologies's 3-Year Revenue Growth Rate

For the Medical Devices subindustry, Anteris Technologies's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anteris Technologies's 3-Year Revenue Growth Rate Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Anteris Technologies's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Anteris Technologies's 3-Year Revenue Growth Rate falls into.



Anteris Technologies 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.


Anteris Technologies  (OTCPK:AMEUF) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.


Anteris Technologies 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Anteris Technologies's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Anteris Technologies (Anteris Technologies) Business Description

Traded in Other Exchanges
Address
Level 3, 9 Sherwood Road, Suite 302, Toowong Tower, Toowong, QLD, AUS, 4066
Anteris Technologies Ltd is a structural heart company engaged in delivering clinically superior solutions that help healthcare professionals create life-changing outcomes for patients. The group's solutions include Anteris' DurAVR transcatheter heart valve for younger patients who need a heart valve that will last their lifetime, as well as DurAVR with its biomimetic design that replicates the normal blood flow of a healthy human aortic valve. The company derives key revenue from Australia and the U.S.